Right now the market is valuing CNAT at zero since market cap equals net cash. Zero is too low.
Yes, last weeks trial results were terrible but but but they did nothing to negate the earlier trial results that did show positive and significant positives from taking the drug. And I know that technically those trials "failed" but the reality is that a lot of good things were learned in those trials.
The clear value for emricasan RIGHT NOW is in combination with other drugs. That has value and is worth something far more than current market cap. It could also change with the upcoming hypertension trial results and LF conclusions.
They are "on base" with the earlier trial results. They struck out with the latest. But they still have two big swings upcoming.
And my belief is even if the next two swings are misses, the drug has proven enough for Novartis to want it and take the entire company in the process. No way will Conatus raise money with a sub-$2 stock.
News 
Market Data 
Discover 
